Evidence map›Paper›PMID 35844833›Full record

ArticleParkinson's disease2022

Nicotine Has a Therapeutic Window of Effectiveness in a

Brady T Mannett, Braden C Capt, Krista Pearman, Lori M Buhlman, John M VandenBrooks, Gerald B Call

Abstract read
In one paragraph

Article in Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Epidemiology of Parkinson's Disease: An Update.Current neurology and neuroscience reports · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brady T MannettArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Braden C CaptArizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
Krista PearmanDepartment of Pharmacology, College of Graduate Studies, Midwestern University, Glendale, AZ 85308, USA.
Lori M BuhlmanBiomedical Science Program, College of Graduate Studies, Midwestern University, Glendale, AZ 85308, USA.ORCID https://orcid.org/0000-0002-2987-839X
John M VandenBrooksDepartment of Physiology, College of Graduate Studies, Midwestern University, Glendale, AZ 85308, USA.ORCID https://orcid.org/0000-0001-6357-1415
Gerald B CallDepartment of Pharmacology, College of Graduate Studies, Midwestern University, Glendale, AZ 85308, USA.ORCID https://orcid.org/0000-0001-8290-1141

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strong epidemiological evidence and studies in models of Parkinson's disease (PD) suggest that nicotine may be therapeutically beneficial in PD patients. However, a number of clinical trials utilizing nicotine in PD patients have had mixed results, indicating that either nicotine is not beneficial in PD patients, or an important aspect of nicotine therapy was absent. We hypothesized that nicotine must be administered early in the adult fly life in order to have beneficial effects. We show that continuous early nicotine administration improves both climbing and flight deficiencies present in homozygous

Identifiers

PMID35844833
PMCPMC9286976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.